Third Harmonic Bio, Inc. (THRD)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
THRD Chart
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?
Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Third Harmonic Bio, Inc. (THRD) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Third Harmonic Bio, Inc. Profile
| - Industry | - Sector | Natalie C. Holles CEO | NASDAQ (NMS) Exchange | 88427A107 CUSIP |
| US Country | 31 Employees | - Last Dividend | - Last Split | 14 Sep 2022 IPO Date |
Overview
Third Harmonic Bio, Inc., a biopharmaceutical company established in Cambridge, Massachusetts, is dedicated to advancing the field of medicine with a focus on devising treatments for allergic and inflammatory diseases. Originally founded as Project IGE, Inc., the company underwent a rebranding to Third Harmonic Bio, Inc. in June 2019. Since its incorporation in 2019, Third Harmonic Bio has made significant strides in addressing a wide range of inflammatory diseases, leveraging its expertise and innovative approaches to improve patient outcomes in dermal, respiratory, and gastrointestinal disease areas.
Products and Services
- Inflammatory Disease Treatments
The core of Third Harmonic Bio's pipeline is dedicated to the discovery and development of novel therapeutics targeting allergic and inflammatory diseases. The company's research efforts span across several key areas:
- Dermal Diseases: Development of treatments aimed at alleviating symptoms and managing conditions related to skin inflammation. This includes a focus on diseases like eczema and psoriasis, where there's a significant need for better therapeutic options.
- Respiratory Diseases: Crafting solutions for respiratory conditions, Third Harmonic Bio works on treatments for diseases such as asthma, where inflammation plays a critical role in the progression and exacerbation of the disease.
- Gastrointestinal Diseases: Addressing inflammatory conditions of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis, with the aim of developing treatments that can effectively manage and potentially achieve remission in patients.
